CTI BioPharma Corp Security Rating

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma's earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia. It also evaluates its pipeline candidate paclitaxel poliglumex, which targets solid tumors.